Julie L. Eiseman, PhD, DABT

Professor of Pharmacology and Chemical Biology University of Pittsburgh Cancer Institute, Basic Research

Julie L. Eiseman, PhD, DABT

jle9@pitt.edu

Office:
Phone: 412-623-3239
Fax:

Department of Pharmacology and Chemical Biology

Professor of Pharmacology and Chemical Biology University of Pittsburgh Cancer Institute, Basic Research

My laboratory is interested in the preclinical development of potential anti-cancer agents and other therapeutic agents. We are involved in the determination of the maximum tolerated doses both single and multiple dose administered to rodents, the preclinical efficacy against both syngeneic tumor in immunocompetent animals and xenografts in immunodeficient animals, the pharmacokinetics of the agent including absorption, distribution, metabolism and excretion, as well as mechanism of action. I have been the Principal Investigator on one of 5 animal pharmacology contracts from the NCI for over 16 years (Current contract: N01-CM2011-00015; New contract as of 7/1/2016: HHSN261201600022I; N02-CM 2016-00022) to conduct preclinical pharmacokinetic and pharmacology evaluations of agents being developed for cancer patients and to extend these studies to Phase I clinical trials through the UM1.

  1. Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, Beumer JH, Rubinstein L, Collins J, Tomaszewski J, Parchment R, Pommier Y, Doroshow JH. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Jul;78(1):73-81. doi: 10.1007/s00280-016-2998-6. Epub 2016 May 11 PMID:27169793
  2. Sehrawat A, Kim SH, Hahm ER, Arlotti JA, Eiseman J, Shiva SS, Rigatti LH, Singh SV. Cancer-selective death of human breast cancer cells by leelamine is mediated by bax and bak activation. Mol Carcinog. 2016 May 5. doi: 10.1002/mc.22497. [Epub ahead of print] PMID:27149078
  3. Wang H, Teriete P, Hu A, Raveendra-Panickar D, Pendelton K, Lazo JS, Eiseman J, Holien T, Misund K, Oliynyk G, Arsenian-Henriksson M, Cosford ND, Sundan A, Prochownik EV Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids. Oncotarget. 2015 Oct 20;6(32):32380-95. doi: 10.18632/oncotarget.6116. PMID:26474287
  4. Teramachi J, Silbermann R, Yang P, Zhao W, Mohammad KS, Guo J, Anderson JL, Zhou D, Feng R, Myint KZ, Maertz N, Beumer JH, Eiseman JL, Windle JJ, Xie XQ, Roodman GD, Kurihara N. Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo. Leukemia. 2016 Feb;30(2):390-8. doi: 10.1038/leu.2015.229. Epub 2015 Aug 19. PMID:26286116
  5. Christner SM, Clausen DM, Beumer JH, Parise RA, Guo J, Huang Y, Dömling AS, Eiseman JL. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction. Cancer Chemother Pharmacol. 2015 Aug;76(2):287-99. doi: 10.1007/s00280-015-2791-y. Epub 2015 Jun 7.PMID:26050209